In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss submitting biologics license applications and working with suppliers.
In this episode of the Ask the Expert video series, Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Siegfried Schmitt, vice president, Technical at Parexel, discuss submitting biologics license applications and working with suppliers. These two topics have a few things in common, most importantly common steps to ensure product quality.
“[The] best way to make sure that you're giving [FDA] what they need is to really talk with them. I think calling up the center, getting your advocate, [and telling them] here's what I'm intending to file early on in your process is where you need to be to understand. Because I would think that this is geared towards not a more common biological but more of a novelty,” says Schniepp in the episode.
Schmitt agrees with getting clarification and addressing gaps in knowledge. “Now, of course, you can ask the agency. [Hopefully you have] some in-house expertise, but again, it is sensible to understand. Where are the gaps? Where would you perhaps need external expert support? [And] as we said with all the other questions before, you need to have a quality system that makes sure that whatever external support [you choose], you select those who are most suitable for your needs and can provide you with some quality expertise.”
Click the video above to watch Sue and Siegfried answer the following questions:
BLA—biologics license application
ICH—International Council for Harmonisation
WHO—World Health Organization
Susan J. Schniepp is distinguished fellow at Regulatory Compliance Associates and a member of Pharmaceutical Technology®'s Editorial Advisory Board.
Siegfried Schmitt is vice president, Technical at Parexel and a member of Pharmaceutical Technology®'s Editorial Advisory Board.
Welcome to the Ask the Expert video series. This series is an extension of the PharmTech Group’s long-running print column in which industry experts answer common quality and regulatory questions from the industry. This new video series will expand on topic areas to include development and manufacturing concerns to help those working in the industry better understand bio/pharmaceutical requirements. Have a question you would like answered? Send it to PTProjects@mmhgroup.com, and it may appear in a future episode or print column.
We hope you enjoy the discussion!
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.